Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CERCA
MCID: CRV035
MIFTS: 77

Cervical Cancer (CERCA)

Categories: Cancer diseases, Genetic diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Cervical Cancer

About this section

MalaCards integrated aliases for Cervical Cancer:

Name: Cervical Cancer 57 12 75 74 37 55 43 3 15 63 72
Uterine Cervical Neoplasms 6 44
Uterine Cervical Neoplasm 12 72
Cervical Cancer, Somatic 57 13
Cervix Cancer 12 74
Neoplasm of Uterine Cervix 12
Tumor of the Cervix Uteri 12
Cancer, Cervical, Somatic 40
Malignant Tumor of Cervix 72
Uterine Cervical Cancer 74
Cervix Uteri Cancer 12
Neoplasms Cervical 55
Cervical Neoplasm 12
Cervix Carcinoma 72
Cervical Cancers 15
Cerca 74

Characteristics:

HPO:

32
cervical cancer:
Inheritance somatic mutation


Classifications:

MalaCards categories:
Global: Genetic diseases Cancer diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:4362
OMIM 57 603956
KEGG 37 H00030
ICD9CM 35 180 180.9
MeSH 44 D002583
NCIt 50 C2940 C9311
SNOMED-CT 68 93752005
ICD10 33 C53 C53.9
UMLS 72 C0007847 C0007873 C0302592 more
Sources

Summaries for Cervical Cancer

About this section
MedlinePlus : 43 The cervix is the lower part of the uterus, the place where a baby grows during pregnancy. Cervical cancer is caused by a virus called HPV. The virus spreads through sexual contact. Most women's bodies are able to fight HPV infection. But sometimes the virus leads to cancer. You're at higher risk if you smoke, have had many children, use birth control pills for a long time, or have HIV infection. Cervical cancer may not cause any symptoms at first. Later, you may have pelvic pain or bleeding from the vagina. It usually takes several years for normal cells in the cervix to turn into cancer cells. Your health care provider can find abnormal cells by doing a Pap test to examine cells from the cervix. You may also have an HPV test. If your results are abnormal, you may need a biopsy or other tests. By getting regular screenings, you can find and treat any problems before they turn into cancer. Treatment may include surgery, radiation therapy, chemotherapy, or a combination. The choice of treatment depends on the size of the tumor, whether the cancer has spread and whether you would like to become pregnant someday. Vaccines can protect against several types of HPV, including some that can cause cancer. NIH: National Cancer Institute

MalaCards based summary : Cervical Cancer, also known as uterine cervical neoplasms, is related to cervix carcinoma and cervix disease, and has symptoms including pelvic pain An important gene associated with Cervical Cancer is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are Human papillomavirus infection and Viral carcinogenesis. The drugs Bethanechol and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include cervix, testes and lymph node, and related phenotypes are neoplasm and abnormality of the cervical spine

Disease Ontology : 12 A female reproductive organ cancer that is located in the cervix.

CDC : 3 Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. When cancer starts in the cervix, it is called cervical cancer. The cervix connects the vagina (birth canal) to the upper part of the uterus. The uterus (or womb) is where a baby grows when a woman is pregnant. All women are at risk for cervical cancer. It occurs most often in women over age 30. Human papillomavirus (HPV) is the main cause of cervical cancer. HPV is a common virus that is passed from one person to another during sex. At least half of sexually active people will have HPV at some point in their lives, but few women will get cervical cancer. Cervical cancer is highly preventable in most Western countries because screening tests and a vaccine to prevent HPV infections are available. When cervical cancer is found early, it is highly treatable and associated with long survival and good quality of life.

KEGG : 37
Cervical cancer is the second largest cause of cancer-related death in women worldwide, and it occurs following persistent infection, sometimes for decades, with a specific subset of human papillomavirus (HPV) types, particularly types 16, 18, 33 and 42. Experimental studies show that the E6 and E7 genes of these high risk HPVs are oncogenes that deregulate key cell cycle controls. The E6 and E7 oncoproteins bind respectively to the p53 and Retinoblastoma (Rb) tumor suppressor proteins, which are involved in the regulation of growth control. The abnormalities in other cellular genes found in cervical cancer, including mutations in ras family of genes, and amplification in EGFR and ERBB2, may also play an important role in carcinogenesis and the aggressiveness of cervical tumors, although to date the role of most of these genetic abnormalities does not appear to be as important as the role of HPV.

UniProtKB/Swiss-Prot : 74 Cervical cancer: A malignant neoplasm of the cervix, typically originating from a dysplastic or premalignant lesion previously present at the active squamocolumnar junction. The transformation from mild dysplastic to invasive carcinoma generally occurs slowly within several years, although the rate of this process varies widely. Carcinoma in situ is particularly known to precede invasive cervical cancer in most cases. Cervical cancer is strongly associated with infection by oncogenic types of human papillomavirus.

PubMed Health : 63 About cervical cancer: Cervical cancer is the term used to describe tumors that can grow at the lower end of the womb. These tumors usually develop from abnormal cell changes at the entrance to the womb from the vagina (the opening of the cervix). Abnormal cell changes can be detected through screening and then removed. A vaccine against viruses that cause cancer (HPV vaccine) can reduce the risk of cervical cancer. The cervix (neck of the womb) is a strong, muscular tube-like structure. The very bottom end of the cervix sticks out into the vagina a little, at the opening of the cervix. The inside of the cervix is lined with a mucous membrane. Glands in the mucous membrane produce a thick liquid (cervical mucus) that acts as a barrier, preventing germs from entering the womb from the vagina.

Wikipedia : 75 Cervical cancer is a cancer arising from the cervix. It is due to the abnormal growth of cells that have... more...

More information from OMIM: 603956
Sources

Related Diseases for Cervical Cancer

About this section

Diseases related to Cervical Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 813)
# Related Disease Score Top Affiliating Genes
1 cervix carcinoma 34.4 TP53 STAT3 FGFR3
2 cervix disease 33.4 TP53 CTNNB1 CCND1
3 papilloma 33.4 TP53 PTEN FGFR3 CCND1
4 squamous cell carcinoma 33.1 TP53 SMAD4 PTEN PIK3CA HRAS HOTAIR
5 adenocarcinoma 33.0 TP53 SMAD4 PTEN PIK3CA HRAS GNAS
6 endometrial cancer 32.8 TP53 STAT3 PTEN PIK3CA MTOR HRAS
7 ovarian cancer 32.4 TP53 STAT3 PVT1 PTEN PIK3CA MIR214
8 lung cancer 32.1 TP53 STAT3 PVT1 PTEN PIK3CA MIR214
9 bladder cancer 32.0 TP53 PVT1 MIR21 HRAS HOTAIR GAS5
10 colorectal cancer 32.0 TP53 STAT3 SMAD4 PVT1 PTEN PIK3CA
11 endometrial adenocarcinoma 32.0 TP53 PTEN ERBB2 CTNNB1
12 glioblastoma multiforme 31.9 TP53 STAT3 PTEN PIK3CA MTOR MIR21
13 esophageal cancer 31.9 TP53 STAT3 SMAD4 PVT1 PTEN PIK3CA
14 breast cancer 31.9 TP53 STAT3 SMAD4 PVT1 PTEN PIK3CA
15 leukemia, acute myeloid 31.9 TP53 STAT3 MTOR MIR21 HRAS HOTAIR
16 melanoma 31.9 TP53 PVT1 PTEN HOTAIR GAS5
17 glioblastoma 31.9 TP53 PTEN PIK3CA MTOR MIR21 HRAS
18 penile cancer 31.8 TP53 PIK3CA CCND1
19 serous cystadenocarcinoma 31.8 TP53 PIK3CA HRAS ERBB2
20 pancreatic cancer 31.8 TP53 STAT3 SMAD4 PVT1 PIK3CA MTOR
21 osteogenic sarcoma 31.8 TP53 PVT1 HOTAIR GAS5
22 lung cancer susceptibility 3 31.8 TP53 STAT3 SMAD4 PIK3CA NFE2L2 HRAS
23 oral cancer 31.7 TP53 MIR21 CCND1
24 gastric cancer 31.7 TP53 SMAD4 PVT1 PTEN PIK3CA MIR214
25 nasopharyngeal carcinoma 31.7 TP53 STAT3 PVT1 PIK3CA HRAS HOTAIR
26 familial adenomatous polyposis 31.7 TP53 SMAD4 CTNNB1 CCND1
27 carcinosarcoma 31.7 TP53 PTEN PIK3CA HRAS ERBB2 CTNNB1
28 transitional cell carcinoma 31.7 TP53 PTEN HRAS FGFR3 ERBB2
29 uterine anomalies 31.7 TP53 PTEN PIK3CA ERBB2 CTNNB1 CCND1
30 small cell cancer of the lung 31.6 TP53 PTEN PIK3CA MIR21 HOTAIR
31 exanthem 31.6 MTOR HRAS ERBB2
32 peutz-jeghers syndrome 31.6 TP53 SMAD4 PTEN CTNNB1
33 prostate cancer 31.6 TP53 STAT3 PVT1 PTEN PIK3CA MTOR
34 adenoma 31.6 TP53 SMAD4 GNAS CTNNB1 CCND1
35 myeloma, multiple 31.5 TP53 STAT3 PVT1 HRAS HOTAIR GAS5
36 cystadenocarcinoma 31.5 TP53 PIK3CA HRAS ERBB2
37 uterine corpus cancer 31.5 TP53 PIK3CA ERBB2
38 kidney cancer 31.5 TP53 PVT1 MTOR MIR214 MIR21 HOTAIR
39 hepatocellular carcinoma 31.4 TP53 STAT3 SMAD4 PVT1 PTEN PIK3CA
40 colorectal adenoma 31.4 TP53 HRAS CTNNB1
41 adenoid cystic carcinoma 31.4 TP53 PTEN PIK3CA HRAS ERBB2 CTNNB1
42 sarcoma 31.4 TP53 PIK3CA MTOR HRAS HOTAIR CTNNB1
43 uterine carcinosarcoma 31.3 TP53 PTEN PIK3CA HRAS ERBB2 CTNNB1
44 laryngeal squamous cell carcinoma 31.3 TP53 MIR21 HOTAIR CCND1
45 ovarian epithelial cancer 31.3 PIK3CA HOTAIR
46 mantle cell lymphoma 31.3 TP53 STAT3 MTOR GAS5 CCND1
47 ovary adenocarcinoma 31.3 TP53 PIK3CA HRAS ERBB2
48 squamous cell carcinoma, head and neck 31.3 TP53 STAT3 SMAD4 PTEN PIK3CA NFE2L2
49 bladder urothelial carcinoma 31.3 TP53 PVT1 PIK3CA NFE2L2 MTOR HRAS
50 ovarian serous cystadenocarcinoma 31.3 TP53 PIK3CA HRAS ERBB2

Comorbidity relations with Cervical Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Hydronephrosis Intestinal Obstruction
Vaginal Cancer

Graphical network of the top 20 diseases related to Cervical Cancer:



Diseases related to Cervical Cancer
Sources

Symptoms & Phenotypes for Cervical Cancer

About this section

Human phenotypes related to Cervical Cancer:

32
# Description HPO Frequency HPO Source Accession
1 neoplasm 32 HP:0002664
2 abnormality of the cervical spine 32 HP:0003319

Clinical features from OMIM:

603956

UMLS symptoms related to Cervical Cancer:


pelvic pain

GenomeRNAi Phenotypes related to Cervical Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.9 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
2 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.8 CTNNB1 ERBB2 FGFR3 HRAS MTOR PTEN
3 Decreased cell migration GR00055-A-1 9.77 CTNNB1 FGFR3 HRAS MTOR PIK3CA
4 Decreased sensitivity to paclitaxel GR00112-A-0 9.26 PTEN SMAD4
5 Increased cell migration GR00055-A-3 9.26 CTNNB1 HRAS MTOR PIK3CA
6 Reduced mammosphere formation GR00396-S 9.23 CCND1 GNAS HRAS MTOR NFE2L2 PTEN

MGI Mouse Phenotypes related to Cervical Cancer:

46 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.42 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
2 cardiovascular system MP:0005385 10.38 CCND1 CTNNB1 ERBB2 GNAS HRAS MTOR
3 cellular MP:0005384 10.38 CCND1 CTNNB1 ERBB2 FGFR3 GNAS MTOR
4 growth/size/body region MP:0005378 10.37 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
5 homeostasis/metabolism MP:0005376 10.36 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
6 endocrine/exocrine gland MP:0005379 10.31 CCND1 CTNNB1 ERBB2 GNAS HRAS MTOR
7 integument MP:0010771 10.3 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
8 craniofacial MP:0005382 10.29 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
9 mortality/aging MP:0010768 10.29 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
10 digestive/alimentary MP:0005381 10.28 CCND1 CTNNB1 ERBB2 FGFR3 HRAS NFE2L2
11 immune system MP:0005387 10.28 CCND1 CTNNB1 FGFR3 GNAS MTOR NFE2L2
12 embryo MP:0005380 10.23 CTNNB1 ERBB2 MTOR NFE2L2 PIK3CA PTEN
13 nervous system MP:0003631 10.22 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
14 neoplasm MP:0002006 10.21 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
15 adipose tissue MP:0005375 10.16 GNAS MTOR NFE2L2 PIK3CA PTEN STAT3
16 muscle MP:0005369 10.11 CTNNB1 ERBB2 GNAS MTOR PIK3CA PTEN
17 normal MP:0002873 10.1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
18 limbs/digits/tail MP:0005371 10.05 CTNNB1 ERBB2 FGFR3 GNAS PTEN SMAD4
19 liver/biliary system MP:0005370 10.04 CTNNB1 GNAS NFE2L2 PTEN SMAD4 STAT3
20 renal/urinary system MP:0005367 9.96 CTNNB1 FGFR3 GNAS HRAS MTOR NFE2L2
21 no phenotypic analysis MP:0003012 9.91 CTNNB1 FGFR3 GNAS HRAS MTOR PIK3CA
22 reproductive system MP:0005389 9.81 CCND1 CTNNB1 ERBB2 FGFR3 PIK3CA PTEN
23 respiratory system MP:0005388 9.7 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
24 skeleton MP:0005390 9.44 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
Sources

Drugs & Therapeutics for Cervical Cancer

About this section

PubMed Health treatment related to Cervical Cancer: 63

The most appropriate type of treatment will mainly depend on the size of the tumor and whether the cancer has spread. If the tumor is discovered at a very early stage, a small surgical procedure (conization) might be enough. If the tumor has already spread to the surrounding tissue, doctors usually recommend having surgery to remove the entire womb (a hysterectomy). The lymph nodes are removed in a wide area around the womb too. Radiotherapy might also be considered. Radiotherapy is still an option even if the tumor can no longer be removed through surgery. In some patients it can be combined with chemotherapy.

Drugs for Cervical Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 458)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bethanechol Approved Phase 4 674-38-4 2370
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
5
Polihexanide Approved, Investigational Phase 4 28757-47-3
6
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
7
Meperidine Approved Phase 4 57-42-1 4058
8
Cantharidin Approved, Investigational Phase 4 56-25-7
9
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
10
Ferrous fumarate Approved Phase 4 141-01-5
11
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
12
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
13 Muscarinic Agonists Phase 4
14 Monophosphoryl lipid A Phase 4
15 Vaccines Phase 4
16 Hypoglycemic Agents Phase 4
17 Contraceptive Agents Phase 4
18 Epoetin alfa Phase 4 113427-24-0
19 Narcotics Phase 4
20 Analgesics, Opioid Phase 4
21 Antidepressive Agents Phase 4
22 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
23 Antidepressive Agents, Second-Generation Phase 4
24 Cytochrome P-450 Enzyme Inhibitors Phase 4
25 Dopamine Agents Phase 4
26 Neurotransmitter Uptake Inhibitors Phase 4
27 Dopamine Uptake Inhibitors Phase 4
28 Autoantibodies Phase 4
29 Disinfectants Phase 4
30 Biguanides Phase 4
31 Calamus Phase 4
32 Progestins Phase 4
33
Medroxyprogesterone Phase 4 520-85-4 10631
34 Fluorodeoxyglucose F18 Phase 4
35 Micronutrients Phase 4
36 Nutrients Phase 4
37 Trace Elements Phase 4
38 Vitamins Phase 4
39
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
40
Hydralazine Approved Phase 3 86-54-4 3637
41
Fluspirilene Approved, Investigational Phase 3 1841-19-6 3396
42
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
43
Vinblastine Approved Phase 3 865-21-4 241903 13342
44
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
45
Metronidazole Approved Phase 2, Phase 3 443-48-1 4173
46
Aluminum hydroxide Approved, Investigational Phase 3 21645-51-2
47
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
48
Dalteparin Approved Phase 3 9005-49-6
49
Eugenol Approved Phase 3 97-53-0 3314
50
Nelfinavir Approved Phase 3 159989-64-7 64143

Interventional clinical trials:

(show top 50) (show all 1501)
# Name Status NCT ID Phase Drugs
1 A Prospective, Open, Randomized, Controlled Clinical Study to Evaluate the Efficacy and Safety of PEG-rhG-CSF in Reducing Neutropenia in Patients With Cervical Cancer Unknown status NCT03206684 Phase 4 PEG-rhG-CSF;rhG-CSF
2 Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China Unknown status NCT01021904 Phase 4
3 A Randomized Controlled Trial Evaluating the Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) in Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer Unknown status NCT02629510 Phase 4 Tachosil
4 Immunogenicity Of A Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, And 18) L1 Virus-Like Particle Vaccine In Male And Female Adolescent Transplant Recipients. Unknown status NCT01101750 Phase 4
5 Can Mindfulness Meditation Limit the Progression and/or Increase the Remission of Cervical Dysplasia? Unknown status NCT00842738 Phase 4
6 Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA Unknown status NCT02910596 Phase 4 bethanechol chloride
7 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
8 HPV Vaccination Impact on Cervical Cancer Screening Program: FASTER-Tlalpan Study in Mexico Unknown status NCT03105856 Phase 4
9 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
10 A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women Completed NCT01544478 Phase 4
11 Effective Surveillance and Impact of HPV Vaccination on Screening for Cervical Cancer in Tuscany Completed NCT02296255 Phase 4
12 Work Package 4: HPV Vaccination of Women in Screening Ages Completed NCT02837926 Phase 4
13 Alternate Dosing Schedules Study for HPV Vaccine Completed NCT00862810 Phase 4
14 Management Of Anemia Under RadioChemotherapy (MARCH): An Open, Randomized Multicenter Study Of The Effect Of NeoRecormon On Treatment Outcome In Patients With Advanced Cervical Cancer Stage IIB -IVA Treated With Primary Simultaneous Radiochemotherapy (Radiotherapy Plus Cisplatin) Completed NCT00046969 Phase 4 cisplatin
15 Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls Completed NCT01173900 Phase 4
16 Patient Navigation in the Safety Net:CONNECTeDD Completed NCT00613275 Phase 4
17 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
18 Does Intraoperative Application of TachoSil Reduce the Number of Lymphocele After Pelvic Lymphadenectomy? Completed NCT03752606 Phase 4
19 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
20 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With Systemic Lupus Erythematosus (SLE): a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
21 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
22 Whether 18F-ALF-NOTA-PRGD2 PET/CT Scan Can Predict the Efficacy and Adverse Events of Apatinib in Patients With Malignancies. Completed NCT03384511 Phase 4 Apatinib
23 A Phase IV, Randomised Study to Evaluate the Immune Responses of UK Adolescent Girls Receiving CervarixTM or GardasilTM Human Papillomavirus Vaccines Completed NCT00956553 Phase 4
24 Safety and Immunogenicity of Cervarixâ„¢ in Human Immunodeficiency Virus Infected Females Completed NCT01031069 Phase 4
25 Evaluation of the Effectiveness of Two Vaccination Strategies Using GlaxoSmithKline Biologicals' HPV Vaccine GSK580299 (Cervarixâ„¢) Administered in Healthy Adolescents Completed NCT00534638 Phase 4
26 Acceptability and Feasibility of a Modified HPV Vaccine Schedule in Brothel Based Female Sex Workers in Peru Completed NCT00925288 Phase 4
27 Follow-up Study to Evaluate the Long-term Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV (580299) Vaccine in Healthy Female Subjects Completed NCT00947115 Phase 4
28 Polyhexamethylene Biguanide Increases the Regression Rate of Human Papillomavirus (HPV) Infection Completed NCT01571141 Phase 4
29 Comparison of Meperidine and Fentanyl on Pain Scale and Quality of Life in Cervical Cancer Patients Receiving Brachytherapy: A Double-blind, Randomized Controlled Trial Completed NCT02684942 Phase 4 Meperidine;Fentanyl
30 Trichloroacetic Acid Versus Cantharone for the Treatment of Perenial Warts Completed NCT03625960 Phase 4 Cantharidin;Trichloroacetic Acid
31 Effectiveness of Home Based Distribution of Hormonal Contraceptives for Women at Risk for Unintended Pregnancy Completed NCT00928538 Phase 4
32 Quadrivalent HPV Vaccination After Effective Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Completed NCT02087384 Phase 4 Placebo
33 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Pilot Study. Recruiting NCT03349463 Phase 4 Fluciclovine F18
34 Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer Compared With 18F FDG PET Recruiting NCT03423082 Phase 4 18F fluciclovine
35 A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study Recruiting NCT03180034 Phase 4
36 Postpartum HPV Vaccination: Acceptability, Uptake and Immunogenicity Recruiting NCT03451071 Phase 4 Gardasil9
37 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study: A Randomized Controlled Trial of the Efficacy of HPV Vaccination in Preventing Transmission of HPV Infection in Heterosexual Couples Recruiting NCT01824537 Phase 4
38 Randomized Controlled Trial to Evaluate the Efficacy of Concurrent Liquid-based Cytology ( LBC) and HPV DNA Testing Versus LBC Alone for the Primary Cervical Cancer Screening Active, not recruiting NCT01895517 Phase 4
39 Randomised Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India Active, not recruiting NCT00923702 Phase 4
40 A Randomized Controlled Trial of Pre-Operative Treatment With Ferrous Fumarate 300 mg Once Daily Versus Placebo in Newly Diagnoses Gynecologic Oncology Patients Who Are Primary Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
41 Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study Active, not recruiting NCT03629886 Phase 4
42 KENya Single-dose HPV-vaccine Efficacy - The KEN-SHE Study Enrolling by invitation NCT03675256 Phase 4
43 Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved Communities Terminated NCT00629993 Phase 4
44 A Post-marketing Surveillance (PMS) Study to Monitor the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in 3,000 Healthy Female Filipino Subjects When Administered According to the Prescribing Information From the Age of 10 Years Onwards. Terminated NCT00730847 Phase 4
45 Randomized Controlled Trial Comparing Concurrent Chemoradiation Versus Concurrent Chemoradiation Followed by Adjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients Unknown status NCT02036164 Phase 3 Cisplatin;Paclitaxel;Carboplatin
46 Doctoral CRP on Clinical and Experimental Studies to Improve Radiotherapy Outcome in AIDS Cancer Patients Unknown status NCT00122746 Phase 3
47 Phase III Randomized Trial of Comparing Chemoradiotherapy vs. Radiotherapy Alone in Lymph Node Negative Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy Unknown status NCT01756170 Phase 3 paclitaxel;cisplatin
48 Phase III Randomized Study of Concurrent Paclitaxel/Cisplatin Chemotherapy and Radiotherapy With or Without Consolidation Chemotherapy in High-Risk Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy Unknown status NCT01755845 Phase 3 paclitaxel;cisplatin
49 Phase III Trial for Primary Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in PET/CT Defined Poor-Prognostic Cervical Cancer Patients Unknown status NCT00842660 Phase 3 Gemzar (gemcitabine)
50 Clinical Study on Docetaxel Plus Cisplatin(TP) Regimen Combined With Postoperative Radiotherapy for Stage Ia2- IIb Cervical Cancer Unknown status NCT01999933 Phase 2, Phase 3 cisplatin（DDP） weekly;docetaxel plus cisplatin;docetaxel plus cisplatin

Search NIH Clinical Center for Cervical Cancer

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Bleomycin
Cisplatin
Ifosfamide
Mitomycin
Pembrolizumab

Cochrane evidence based reviews: uterine cervical neoplasms

Sources

Genetic Tests for Cervical Cancer

About this section
Sources

Anatomical Context for Cervical Cancer

About this section

MalaCards organs/tissues related to Cervical Cancer:

41
Cervix, Testes, Lymph Node, Breast, Uterus, T Cells, Lung

The Foundational Model of Anatomy Ontology organs/tissues related to Cervical Cancer:

19
Cervix
Sources

Publications for Cervical Cancer

About this section

Articles related to Cervical Cancer:

(show top 50) (show all 30278)
# Title Authors PMID Year
1
Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. 9 38 8 71
1349102 1992
2
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. 8 71
10471491 1999
3
Somatic LKB1 mutations promote cervical cancer progression. 9 38 8
19340305 2009
4
PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. 38 8
23266353 2013
5
Effect of radiotherapy on the survival of cervical cancer patients: An analysis based on SEER database. 38 17
31348242 2019
6
Landscape of genomic alterations in cervical carcinomas. 8
24390348 2014
7
MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. 38 88
19859982 2009
8
MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells. 38 88
19682430 2009
9
Patterns of known and novel small RNAs in human cervical cancer. 38 88
17616659 2007
10
Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. 8
17360030 2007
11
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. 71
15772091 2005
12
Genetic link to cervical tumours. 8
10403244 1999
13
Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. 71
8589699 1995
14
Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. 8
8041728 1994
15
Mutational hotspot in the p53 gene in human hepatocellular carcinomas. 71
1849234 1991
16
A genetic model for colorectal tumorigenesis. 8
2188735 1990
17
Association of C8orf4 expression with its methylation status, aberrant β-catenin expression, and the development of cervical squamous cell carcinoma. 17
31374065 2019
18
A study on the correlation between radiation field size and gamma index passing rate for MatriXX. 17
31348271 2019
19
HIF-1 and NDRG2 contribute to hypoxia-induced radioresistance of cervical cancer Hela cells. 9 38
20206160 2010
20
DeltaNp63alpha repression of the Notch1 gene supports the proliferative capacity of normal human keratinocytes and cervical cancer cells. 9 38
20442293 2010
21
ARL6IP1 mediates cisplatin-induced apoptosis in CaSki cervical cancer cells. 9 38
20372863 2010
22
Low expression of human histocompatibility soluble leukocyte antigen-G (HLA-G5) in invasive cervical cancer with and without metastasis, associated with papilloma virus (HPV). 9 38
19786613 2010
23
Analysis of expression and structure of the TSG101 gene in cervical cancer cells. 9 38
20372822 2010
24
TGF-beta induces telomerase-dependent pancreatic tumor cell cycle arrest. 9 38
20138964 2010
25
Activity of protein kinase CK2 uncouples Bid cleavage from caspase-8 activation. 9 38
20356928 2010
26
Activating transcription factor 3 activates p53 by preventing E6-associated protein from binding to E6. 9 38
20167600 2010
27
Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. 9 38
20429915 2010
28
Homozygous deletion of the STK11/LKB1 locus and the generation of novel fusion transcripts in cervical cancer cells. 9 38
20193846 2010
29
Fibronectin-integrin mediated signaling in human cervical cancer cells (SiHa). 9 38
19816757 2010
30
Oncosuppressor proteins of fragile sites are reduced in cervical cancer. 9 38
19700237 2010
31
TP53, MDM2, NQO1, and susceptibility to cervical cancer. 9 38
20200430 2010
32
Human papillomavirus type 16 E5 protein inhibits hydrogen-peroxide-induced apoptosis by stimulating ubiquitin-proteasome-mediated degradation of Bax in human cervical cancer cells. 9 38
20015862 2010
33
Inhibition of metastasis-associated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells suppresses cell proliferation and invasion. 9 38
20213048 2010
34
Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. 9 38
19913895 2010
35
Anti-angiogenesis agents in metastatic or recurrent cervical cancer. 9 38
19861227 2010
36
Novel missense mutation in FHIT gene: interpreting the effect in HPV-mediated cervical cancer in Indian women. 9 38
19730990 2010
37
[Exploring the issue of cervical cancer prevention and control in women living with HIV/AIDS]. 9 38
20127625 2010
38
Use of tissue microarray to facilitate oncology research. 9 38
20217582 2010
39
Gene promoter methylation patterns throughout the process of cervical carcinogenesis. 9 38
20208141 2010
40
The effect of cyclooxygenase-2 expression on tumor volume response in patients treated with radiotherapy for uterine cervical cancer. 9 38
19949677 2009
41
Novel ultrasound-targeted microbubble destruction mediated short hairpin RNA plasmid transfection targeting survivin inhibits gene expression and induces apoptosis of HeLa cells. 9 38
18991017 2009
42
[Mechanism of anti-tumor effect of HIF-1alpha silencing on cervical cancer in nude mice]. 9 38
20137345 2009
43
Protective role of cytosolic 2-cys peroxiredoxin in the TNF-alpha-induced apoptotic death of human cancer cells. 9 38
19646526 2009
44
Reactive oxygen species-dependent activation of Bax and poly(ADP-ribose) polymerase-1 is required for mitochondrial cell death induced by triterpenoid pristimerin in human cervical cancer cells. 9 38
19574249 2009
45
Cooperation of decay-accelerating factor and membrane cofactor protein in regulating survival of human cervical cancer cells. 9 38
19878546 2009
46
Folate status and aberrant DNA methylation are associated with HPV infection and cervical pathogenesis. 9 38
19755648 2009
47
Tristetraprolin: a weapon against HPV-induced cervical cancer? 9 38
20157555 2009
48
Immunohistochemical expression of ubiquitin and telomerase in cervical cancer. 9 38
19680685 2009
49
The mRNA decay factor tristetraprolin (TTP) induces senescence in human papillomavirus-transformed cervical cancer cells by targeting E6-AP ubiquitin ligase. 9 38
20157568 2009
50
Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86. 9 38
19672258 2009
Sources

Variations for Cervical Cancer

About this section

ClinVar genetic disease variations for Cervical Cancer:

6 (show top 50) (show all 142)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 PTEN NM_000314.7(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic rs121909224 10:89692904-89692904 10:87933147-87933147
2 PIK3CA NM_006218.4(PIK3CA): c.2176G> A (p.Glu726Lys) single nucleotide variant Pathogenic rs867262025 3:178938934-178938934 3:179221146-179221146
3 TP53 NM_000546.5(TP53): c.713G> T (p.Cys238Phe) single nucleotide variant Pathogenic rs730882005 17:7577568-7577568 17:7674250-7674250
4 PTEN NM_000314.7(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 10:89692905-89692905 10:87933148-87933148
5 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 18:48591918-48591918 18:51065548-51065548
6 HRAS NM_005343.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
7 HRAS NM_005343.4(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 11:534288-534288 11:534288-534288
8 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 11:534286-534286 11:534286-534286
9 HRAS NM_005343.4(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
10 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
11 PIK3CA NM_006218.4(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
12 FGFR3 NM_000142.4(FGFR3): c.1620C> G (p.Asn540Lys) single nucleotide variant Pathogenic rs28933068 4:1807371-1807371 4:1805644-1805644
13 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic rs121913483 4:1803568-1803568 4:1801841-1801841
14 FGFR3 NM_000142.4(FGFR3): c.749C> G (p.Pro250Arg) single nucleotide variant Pathogenic rs4647924 4:1803571-1803571 4:1801844-1801844
15 PIK3CA NM_006218.4(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 3:178936092-178936092 3:179218304-179218304
16 PIK3CA NM_006218.4(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 3:178952084-178952084 3:179234296-179234296
17 PIK3CA NM_006218.4(PIK3CA): c.1637A> G (p.Gln546Arg) single nucleotide variant Pathogenic rs397517201 3:178936095-178936095 3:179218307-179218307
18 FGFR3 NM_000142.4(FGFR3): c.1949A> C (p.Lys650Thr) single nucleotide variant Pathogenic rs121913105 4:1807890-1807890 4:1806163-1806163
19 SMAD4 NM_005359.5(SMAD4): c.1082G> A (p.Arg361His) single nucleotide variant Pathogenic rs377767347 18:48591919-48591919 18:51065549-51065549
20 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic rs121913482 4:1803564-1803564 4:1801837-1801837
21 TP53 NM_000546.5(TP53): c.712T> C (p.Cys238Arg) single nucleotide variant Pathogenic rs1057519981 17:7577569-7577569 17:7674251-7674251
22 PIK3CA NM_006218.4(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 3:178936082-178936082 3:179218294-179218294
23 HRAS NM_005343.4(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 11:534286-534286 11:534286-534286
24 PIK3CA NM_006218.4(PIK3CA): c.353G> A (p.Gly118Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587777790 3:178917478-178917478 3:179199690-179199690
25 MTOR NM_004958.4(MTOR): c.6644C> T (p.Ser2215Phe) single nucleotide variant Pathogenic/Likely pathogenic rs587777894 1:11184573-11184573 1:11124516-11124516
26 HRAS NM_005343.4(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 11:534285-534285 11:534285-534285
27 GNAS NM_001077488.4(GNAS): c.605G> T (p.Arg202Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 20:57484421-57484421 20:58909366-58909366
28 PIK3CA NM_006218.4(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 3:178936093-178936093 3:179218305-179218305
29 GNAS NM_001077488.4(GNAS): c.604C> T (p.Arg202Cys) single nucleotide variant Pathogenic/Likely pathogenic rs11554273 20:57484420-57484420 20:58909365-58909365
30 GNAS NM_001077488.4(GNAS): c.605G> A (p.Arg202His) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 20:57484421-57484421 20:58909366-58909366
31 CTNNB1 NM_001904.4(CTNNB1): c.95A> G (p.Asp32Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913396 3:41266098-41266098 3:41224607-41224607
32 CTNNB1 NM_001904.4(CTNNB1): c.110C> G (p.Ser37Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 3:41266113-41266113 3:41224622-41224622
33 CTNNB1 NM_001904.4(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 3:41266097-41266097 3:41224606-41224606
34 CTNNB1 NM_001904.4(CTNNB1): c.110C> T (p.Ser37Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 3:41266113-41266113 3:41224622-41224622
35 PIK3CA NM_006218.4(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 3:178936094-178936094 3:179218306-179218306
36 PIK3CA NM_006218.4(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 3:178936091-178936091 3:179218303-179218303
37 PIK3CA NM_006218.4(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 3:178936092-178936092 3:179218304-179218304
38 PIK3CA NM_006218.4(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 3:178936094-178936094 3:179218306-179218306
39 HRAS NM_005343.4(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 11:533467-533467 11:533467-533467
40 PIK3CA NM_006218.4(PIK3CA): c.1030G> A (p.Val344Met) single nucleotide variant Pathogenic/Likely pathogenic rs1057519942 3:178921548-178921548 3:179203760-179203760
41 PTEN NM_000314.7(PTEN): c.389G> T (p.Arg130Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 10:89692905-89692905 10:87933148-87933148
42 NFE2L2 NM_001313903.1(NFE2L2): c.93+142G> A single nucleotide variant Pathogenic/Likely pathogenic rs1057519922 2:178098810-178098810 2:177234082-177234082
43 ERBB2 NM_004448.3(ERBB2): c.2305G> C (p.Asp769His) single nucleotide variant Pathogenic/Likely pathogenic rs121913468 17:37880261-37880261 17:39724008-39724008
44 ERBB2 NM_004448.3(ERBB2): c.2305G> T (p.Asp769Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913468 17:37880261-37880261 17:39724008-39724008
45 CTNNB1 NM_001904.4(CTNNB1): c.110C> A (p.Ser37Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 3:41266113-41266113 3:41224622-41224622
46 PIK3CA NM_006218.4(PIK3CA): c.1637A> C (p.Gln546Pro) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 3:178936095-178936095 3:179218307-179218307
47 PIK3CA NM_006218.4(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs104886003 3:178936091-178936091 3:179218303-179218303
48 PIK3CA NM_006218.4(PIK3CA): c.1637A> T (p.Gln546Leu) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 3:178936095-178936095 3:179218307-179218307
49 MTOR NM_004958.4(MTOR): c.6644C> A (p.Ser2215Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587777894 1:11184573-11184573 1:11124516-11124516
50 PIK3CA NM_006218.4(PIK3CA): c.1624G> C (p.Glu542Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 3:178936082-178936082 3:179218294-179218294

UniProtKB/Swiss-Prot genetic disease variations for Cervical Cancer:

74
# Symbol AA change Variation ID SNP ID
1 FGFR3 p.Ser249Cys VAR_004149 rs121913483

Copy number variations for Cervical Cancer from CNVD:

7 (show top 50) (show all 142)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13747 1 1 27800000 Gain EPHB2 Cervical cancer
2 16425 1 124300000 247249719 Arm Cervical cancer
3 30310 1 241700000 247249719 Gain Cervical cancer
4 31746 1 30500000 163800000 Gain AIM2 Cervical cancer
5 32175 1 34400000 39600000 Gain CDCA8 Cervical cancer
6 47124 10 89600000 98000000 Loss PTEN Cervical cancer
7 48645 11 101600000 102400000 Amplification MMP1 Cervical cancer
8 48646 11 101600000 102400000 Amplification MMP13 Cervical cancer
9 51761 11 130300000 134452384 Loss Cervical cancer
10 51791 11 130800000 135006516 Loss HNT Cervical cancer
11 51792 11 130800000 135006516 Loss OPCML Cervical cancer
12 55435 11 52900000 134452384 Loss Cervical cancer
13 57095 11 63100000 130300000 Loss INT2 Cervical cancer
14 57096 11 63100000 130300000 Loss MEN1 Cervical cancer
15 57097 6 99389300 99393387 Loss POUF3 Cervical cancer
16 57098 11 63100000 130300000 Loss TRIM29 Cervical cancer
17 59362 11 74700000 85300000 Gain Cervical cancer
18 77051 13 39500000 52200000 Loss RB Cervical cancer
19 81044 14 100400000 106368585 Gain AKT1 Cervical cancer
20 97280 16 1 40700000 Loss Cervical cancer
21 106741 17 1 11200000 Loss TP53 Cervical cancer
22 108734 17 22200000 28800000 Loss CCL2 Cervical cancer
23 109725 17 28500000 29700000 Amplification Cervical cancer
24 109738 17 28800000 35400000 Amplification ERBB2 Cervical cancer
25 111034 17 34900000 35300000 Amplification Cervical cancer
26 111283 17 35400000 54900000 Amplification ABCC3 Cervical cancer
27 112092 17 37856253 37884915 Amplification ERBB2 Cervical cancer
28 112304 17 38544772 38574202 Amplification TOP2A Cervical cancer
29 117589 17 72900000 78774742 Gain Cervical cancer
30 124103 19 1 30200000 Gain Cervical cancer
31 124104 19 1 30200000 Loss Cervical cancer
32 124177 19 1 6900000 Gain SMARCA4 Cervical cancer
33 124219 19 1 6900000 Gain Cervical cancer
34 124597 19 1156797 1179434 Deletion LKB1 Cervical Cancer
35 124598 19 1156797 1179434 Deletion LKB1 Cervical cancer
36 130163 19 47800000 57600000 Gain LIG1 Cervical cancer
37 134165 19 9500000 14500000 Gain Cervical cancer
38 140388 2 197100000 242951149 Loss CASP10 Cervical cancer
39 140389 2 197100000 242951149 Loss CFLAR Cervical cancer
40 140390 2 197100000 242951149 Loss PPP1R7 Cervical cancer
41 151917 20 27100000 28400000 Amplification AHCY Cervical cancer
42 151918 20 27100000 28400000 Amplification ASXL1 Cervical cancer
43 151919 20 27100000 28400000 Amplification C20orf20 Cervical cancer
44 151920 20 27100000 28400000 Amplification E2F1 Cervical cancer
45 151921 20 27100000 28400000 Amplification GSS Cervical cancer
46 151922 20 27100000 28400000 Amplification KIF3B Cervical cancer
47 151923 20 27100000 28400000 Amplification POFUT1 Cervical cancer
48 151924 20 27100000 28400000 Amplification TPX2 Cervical cancer
49 153446 20 37100000 41100000 Gain AIB1 Cervical cancer
50 153736 20 41100000 49200000 Amplification ADNP Cervical cancer
Sources

Expression for Cervical Cancer

About this section
Search GEO for disease gene expression data for Cervical Cancer.
Sources

Pathways for Cervical Cancer

About this section

Pathways related to Cervical Cancer according to KEGG:

37
# Name Kegg Source Accession
1 Human papillomavirus infection hsa05165
2 Viral carcinogenesis hsa05203

Pathways related to Cervical Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 105)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 64
Show member pathways
 13.95 TP53 STAT3 SMAD4 PTEN MTOR HRAS
2
TGF-Beta Pathway 64
Show member pathways
 13.63 TP53 STAT3 SMAD4 PIK3CA MTOR HRAS
3
Akt Signaling 64
Show member pathways
 13.51 TP53 STAT3 PTEN MTOR HRAS GNAS
4
Cytokine Signaling in Immune system 66
Show member pathways
 13.43 TP53 STAT3 PIK3CA HRAS FGFR3 ERBB2
5
IL-2 Pathway 64
Show member pathways
 13.31 TP53 STAT3 PTEN MTOR HRAS GNAS
6
Phospholipase-C Pathway 64
Show member pathways
 13.14 TP53 PTEN MTOR HRAS GNAS FGFR3
7
PI3K-Akt signaling pathway 37
Show member pathways
 13.04 TP53 PTEN PIK3CA MTOR HRAS GNAS
8
TNFR1 Pathway 64
Show member pathways
 13.03 TP53 PTEN PIK3CA MTOR HRAS CTNNB1
9
Human cytomegalovirus infection 37
Show member pathways
 13.03 TP53 STAT3 SMAD4 PTEN PIK3CA MTOR
10
Focal Adhesion 37 1
Show member pathways
 13.02 STAT3 PTEN PIK3CA HRAS ERBB2 CTNNB1
11
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 13 STAT3 PTEN PIK3CA MTOR HRAS ERBB2
12
NFAT and Cardiac Hypertrophy 64
Show member pathways
 13 STAT3 PTEN PIK3CA MTOR HRAS GNAS
13
Endometrial cancer 37
Show member pathways
 12.92 TP53 STAT3 SMAD4 PTEN PIK3CA MTOR
14
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 65
Show member pathways
 12.88 STAT3 PTEN PIK3CA MTOR HRAS CCND1
15
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 12.87 TP53 PTEN PIK3CA MTOR HRAS FGFR3
16
Development HGF signaling pathway 22
Show member pathways
 12.82 TP53 STAT3 PTEN PIK3CA MTOR HRAS
17
Ras signaling pathway 37
Show member pathways
 12.81 PIK3CA HRAS GNAS FGFR3 CTNNB1
18
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.81 PTEN PIK3CA MTOR HRAS GNAS CTNNB1
19
Gastric cancer 37
Show member pathways
 12.77 TP53 SMAD4 PTEN PIK3CA NFE2L2 MTOR
20
Glioma 37
Show member pathways
 12.73 TP53 STAT3 PTEN PIK3CA MTOR HRAS
21
ErbB signaling pathway 37 1
Show member pathways
 12.72 TP53 STAT3 PIK3CA MTOR HRAS ERBB2
22
Immune response IL-23 signaling pathway 22
Show member pathways
 12.71 TP53 STAT3 PIK3CA HRAS ERBB2 CTNNB1
23
mTOR signaling pathway (KEGG) 37
Show member pathways
 12.64 TP53 PTEN PIK3CA MTOR HRAS FGFR3
24
Prolactin Signaling Pathway 1 37
Show member pathways
 12.62 STAT3 PTEN PIK3CA MTOR HRAS ERBB2
25
Apoptosis Pathway 71
Show member pathways
 12.56 TP53 PIK3CA MTOR HRAS FGFR3 ERBB2
26
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.54 TP53 PIK3CA MTOR HRAS CCND1
27
MET promotes cell motility 66
Show member pathways
 12.53 STAT3 PIK3CA MTOR HRAS
28
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.53 STAT3 PIK3CA MTOR HRAS FGFR3 ERBB2
29
JAK-STAT signaling pathway (KEGG) 37
Show member pathways
 12.5 STAT3 PIK3CA MTOR HRAS CCND1
30
Human T-cell leukemia virus 1 infection 37
12.5 TP53 SMAD4 PIK3CA HRAS CTNNB1 CCND1
31
Development IGF-1 receptor signaling 22
Show member pathways
 12.5 TP53 STAT3 PTEN PIK3CA MTOR HRAS
32
Phospholipase D signaling pathway 37
Show member pathways
 12.47 PIK3CA MTOR HRAS GNAS
33
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.46 STAT3 PIK3CA HRAS CTNNB1
34
Development A3 receptor signaling 22
Show member pathways
 12.44 STAT3 PIK3CA HRAS CTNNB1 CCND1
35
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.44 PIK3CA HRAS GNAS ERBB2 CCND1
36
Viral carcinogenesis 37
12.41 TP53 STAT3 PIK3CA HRAS CCND1
37
B Cell Receptor Signaling Pathway (sino) 67
Show member pathways
 12.4 PTEN PIK3CA MTOR HRAS
38
Toll Comparative Pathway 64
Show member pathways
 12.38 TP53 PIK3CA HRAS GNAS
39
Colorectal Cancer Metastasis 64
12.35 TP53 STAT3 SMAD4 GNAS CTNNB1 CCND1
40
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 12.33 TP53 STAT3 MTOR HRAS
41
Cellular senescence (KEGG) 37
12.33 TP53 PTEN PIK3CA MTOR HRAS CCND1
42
EGF/EGFR Signaling Pathway 1
12.31 STAT3 PTEN MTOR HRAS ERBB2
43
Integrated Breast Cancer Pathway 1
12.3 TP53 SMAD4 PTEN MTOR CTNNB1 CCND1
44
Development EGFR signaling via small GTPases 22
Show member pathways
 12.28 STAT3 PTEN PIK3CA HRAS GNAS ERBB2
45
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 12.28 TP53 PTEN PIK3CA MTOR HRAS FGFR3
46
Kit receptor signaling pathway 1
Show member pathways
 12.27 STAT3 PTEN PIK3CA HRAS
47
MicroRNAs in cardiomyocyte hypertrophy 1
Show member pathways
 12.26 STAT3 PIK3CA MTOR CTNNB1
48
Signaling by FGFR2 in disease 66
Show member pathways
 12.26 STAT3 PIK3CA HRAS FGFR3
49
mTOR Pathway 71
Show member pathways
 12.26 TP53 PIK3CA MTOR HRAS
50
Longevity regulating pathway 37
Show member pathways
 12.23 TP53 PIK3CA MTOR HRAS
Sources

GO Terms for Cervical Cancer

About this section

Cellular components related to Cervical Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.47 TP53 STAT3 SMAD4 PTEN PIK3CA NFE2L2

Biological processes related to Cervical Cancer according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.95 MIR214 MIR21 HRAS CTNNB1
2 response to drug GO:0042493 9.95 STAT3 PTEN GNAS CTNNB1 CCND1
3 positive regulation of cell proliferation GO:0008284 9.91 STAT3 PTEN MIR21 HRAS FGFR3 CTNNB1
4 positive regulation of protein phosphorylation GO:0001934 9.85 MTOR MIR21 HRAS ERBB2 CCND1
5 positive regulation of MAPK cascade GO:0043410 9.84 HRAS FGFR3 ERBB2 CTNNB1
6 negative regulation of apoptotic process GO:0043066 9.83 TP53 STAT3 PTEN MIR21 CTNNB1
7 response to estradiol GO:0032355 9.81 STAT3 PTEN CTNNB1 CCND1
8 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.8 PTEN MIR21 HRAS FGFR3
9 positive regulation of protein kinase B signaling GO:0051897 9.8 PIK3CA MTOR MIR21 FGFR3 ERBB2
10 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.78 SMAD4 PTEN MIR21
11 negative regulation of cell death GO:0060548 9.77 STAT3 SMAD4 NFE2L2
12 positive regulation of osteoblast differentiation GO:0045669 9.74 MIR21 GNAS CTNNB1
13 cell aging GO:0007569 9.7 TP53 MTOR HRAS
14 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.65 NFE2L2 MIR214 MIR21
15 cellular response to hypoxia GO:0071456 9.65 TP53 PTEN NFE2L2 MTOR MIR214
16 response to leptin GO:0044321 9.64 STAT3 CCND1
17 regulation of protein kinase B signaling GO:0051896 9.64 MTOR MIR21
18 regulation of mitochondrial membrane permeability GO:0046902 9.63 TP53 STAT3
19 anoikis GO:0043276 9.62 PIK3CA MTOR
20 negative regulation of cell size GO:0045792 9.62 PTEN MTOR
21 positive regulation of epithelial to mesenchymal transition GO:0010718 9.62 SMAD4 MTOR MIR21 CTNNB1
22 cellular response to leptin stimulus GO:0044320 9.61 STAT3 PTEN
23 positive regulation of metalloendopeptidase activity GO:1904685 9.6 STAT3 MIR21
24 mitotic G1 DNA damage checkpoint GO:0031571 9.58 TP53 CCND1
25 endothelial tube morphogenesis GO:0061154 9.58 MIR21 CTNNB1
26 hair follicle placode formation GO:0060789 9.56 GNAS CTNNB1
27 negative regulation of cell proliferation GO:0008285 9.56 TP53 STAT3 SMAD4 PTEN MIR214 MIR21
28 cell proliferation GO:0008283 9.55 TP53 STAT3 SMAD4 PTEN CTNNB1
29 positive regulation of transcription by RNA polymerase III GO:0045945 9.33 MTOR
30 positive regulation of gene expression GO:0010628 9.28 TP53 STAT3 PTEN NFE2L2 MTOR MIR21

Molecular functions related to Cervical Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.87 TP53 STAT3 SMAD4 PTEN MTOR FGFR3
2 transcription regulatory region DNA binding GO:0044212 9.71 TP53 STAT3 SMAD4 NFE2L2
3 transcription factor binding GO:0008134 9.55 TP53 STAT3 NFE2L2 CTNNB1 CCND1
4 I-SMAD binding GO:0070411 9.43 SMAD4 CTNNB1
5 RNA polymerase II transcription factor binding GO:0001085 9.43 TP53 SMAD4 CTNNB1
6 protein kinase binding GO:0019901 9.43 TP53 STAT3 PTEN MTOR CTNNB1 CCND1
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.07 PIK3CA
8 protein phosphatase binding GO:0019903 8.92 TP53 STAT3 ERBB2 CTNNB1
Sources

Sources for Cervical Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....